Risk-based Management Guidelines for the abnormal screening results, including post-colposcopy or post-treatment scenarios. Enduring Guidelines apply this approach to new technologies that emerge and novel clinical scenarios that were not previously addressed.

www.asccp.org

The ASCCP Risk-Based Management Consensus Guidelines represent a consensus of nearly 20 professional organizations and patient advocates, convened by ASCCP; they are designed to safely triage individuals with abnormal cervical cancer screening results.

Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations. USPSTF Screening Guidelines ASCCP endorses the United States Preventative Services Task Force (USPSTF) cervical cancer screening guidelines.

The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.

Jul 15, 2009 · New data have emerged since publication of the American Society for Colposcopy and Cervical Pathology's 2001 consensus guidelines for management of abnormal cervical cytology and histology.

Cervical Pathology (ASCCP) guidelines for cervical cancer screening. 2) Discuss special populations and considerations for screening outside the typical screening. 3) Apply management strategies for abnormal pap and HPV results by using the ASCCP application. 4) Understand the general principles and procedure of colposcopy

The Society of Gynecologic Oncology recently completed guidelines on the management of AIS; recommendations were adopted by the 2019 ASCCP Risk-Based Management Guidelines consensus committee and are summarized below.

Mar 11, 2024 · The American Society of Colposcopy and Cervical Pathology (ASCCP), has published their enduring consensus guidelines and now recognizes the use of p16/Ki-67 dual-stain biomarkers (CINtec® PLUS Cytology) as an important

-Follow general population screening guidelines Systemic lupus erythematosus and rheumatoid arthritis on immunosuppressant treatments-Cytology is recommended if younger than 30 y-Co-testing is preferred, but cytology is acceptable if 30 y or older-If using cytology alone, perform annual cervical cytology. If results of